4D Molecular Correlations
FDMT Stock | USD 3.57 0.13 3.51% |
The current 90-days correlation between 4D Molecular Therapeutics and Black Diamond Therapeutics is 0.31 (i.e., Weak diversification). The correlation of 4D Molecular is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
4D Molecular Correlation With Market
Average diversification
The correlation between 4D Molecular Therapeutics and DJI is 0.14 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding 4D Molecular Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
FDMT |
Moving together with FDMT Stock
0.73 | CDIOW | Cardio Diagnostics | PairCorr |
0.76 | ELVN | Enliven Therapeutics Downward Rally | PairCorr |
0.71 | SCLX | Scilex Holding | PairCorr |
0.78 | ASMB | Assembly Biosciences Earnings Call Today | PairCorr |
0.67 | CDIO | Cardio Diagnostics | PairCorr |
0.77 | CRNX | Crinetics Pharmaceuticals | PairCorr |
0.67 | DIS | Walt Disney | PairCorr |
0.64 | MSFT | Microsoft Aggressive Push | PairCorr |
Moving against FDMT Stock
0.72 | LUCD | Lucid Diagnostics | PairCorr |
0.62 | WM | Waste Management | PairCorr |
0.54 | GE | GE Aerospace | PairCorr |
0.37 | PLX | Protalix Biotherapeutics | PairCorr |
0.78 | CVX | Chevron Corp | PairCorr |
0.75 | JNJ | Johnson Johnson | PairCorr |
0.7 | T | ATT Inc Aggressive Push | PairCorr |
0.69 | XOM | Exxon Mobil Corp Earnings Call This Week | PairCorr |
0.61 | MMM | 3M Company | PairCorr |
0.59 | INTC | Intel Sell-off Trend | PairCorr |
0.44 | CSCO | Cisco Systems | PairCorr |
0.39 | IBM | International Business | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between FDMT Stock performing well and 4D Molecular Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze 4D Molecular's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
TCRR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
RVMD | 1.77 | (0.23) | 0.00 | (0.16) | 0.00 | 4.37 | 11.35 | |||
BDTX | 3.96 | (0.56) | 0.00 | (6.69) | 0.00 | 7.09 | 29.04 | |||
BCEL | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
PASG | 4.02 | (0.24) | 0.00 | (0.22) | 0.00 | 7.69 | 56.48 | |||
IPSC | 2.99 | (1.08) | 0.00 | (0.55) | 0.00 | 5.88 | 17.02 | |||
EWTX | 2.65 | (0.45) | 0.00 | (0.93) | 0.00 | 4.89 | 17.09 | |||
CCCC | 3.36 | (0.86) | 0.00 | (0.31) | 0.00 | 6.86 | 19.46 | |||
MLYS | 4.36 | 0.68 | 0.14 | (0.35) | 4.26 | 10.04 | 50.53 | |||
CGEM | 2.58 | (0.45) | 0.00 | (0.77) | 0.00 | 5.13 | 15.27 |
4D Molecular Corporate Management
FAAAAI FAAP | Senior Pulmonology | Profile | |
Christopher Simms | Chief Officer | Profile | |
Uneek Mehra | Chief Officer | Profile | |
JD Esq | Chief Officer | Profile | |
Mike Zanoni | VP Relations | Profile | |
Noriyuki MD | Chief Officer | Profile |